Oxigene’s developing cancer treatment meets safety goals in midstage study

Oxigene drug meets safety goals in study

SOUTH SAN FRANCISCO, Calif. — Development-stage biotechnology company Oxigene Inc. said Tuesday its lung cancer treatment candidate Zybrestat met safety goals in a midstage study.

The company said interim data from the Phase II clinical trial showed that the drug, which is part of a combination treatment, appeared to be well-tolerated, with no significant toxicities.

Shares of Oxigene rose 4 cents, or 2.8 percent, to $1.49 in afternoon trading. The stock has traded between 52 cents and $2.78 over the last 52 weeks.